Novo Nordisk Cuts Prices of Ozempic and Wegovy Starting January 2027

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 25, 2026.

via HealthDay

WEDNESDAY, Feb. 25, 2026 — Some of the most popular diabetes and weight-loss drugs in the U.S. will soon cost a lot less.

Novo Nordisk announced Tuesday that it will cut U.S. list prices of Ozempic and Wegovy by up to 50% starting next year.

The lower prices will take effect Jan. 1, 2027, the same time that reduced prices begin under Medicare plans for older folks.

As part of the change, Ozempic and Wegovy will each cost about $675 per month. That’s half the current price of Wegovy and about a 35% drop for Ozempic, which is used to help treat diabetes. Both are injectable drugs.

The company said the price cuts will also apply to Wegovy pills and Rybelsus, another diabetes medication. All doses of these drugs are included.

Novo Nordisk said the move aligns with its goal of making these medicines, commonly known as GLP-1s, more affordable as competition grows.

The market for these drugs has become more crowded in recent years. At the same time, more people are buying them without insurance, making pricing an even bigger concern.

Sources

  • NBC News, Feb. 24, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-02-26 02:01

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords